Sutro Biopharma Inc
Company Profile
Business description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Contact
111 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 881-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
244
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.50 | 5.00 | -0.05% |
| CAC 40 | 7,818.22 | 78.71 | -1.00% |
| DAX 40 | 23,329.24 | 419.62 | -1.77% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,195.66 | 81.37 | -0.88% |
| HKSE | 26,438.51 | 8.05 | -0.03% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,821.03 | 81.24 | -0.18% |
| NZX 50 Index | 13,166.69 | 68.20 | -0.52% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,841.70 | 6.80 | -0.08% |
| SSE Composite Index | 3,859.56 | 2.30 | -0.06% |